• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

4 March 2019

Palynziq (pegvaliase), new treatment for phenylketonuria, a rare inherited metabolic disease


0 Comments3 Minutes

4 March 2019

Zynquista (sotagliflozin), New add-on treatment to insulin for treatment of certain patients with type 1 diabetes


0 Comments4 Minutes

18 February 2019

The World Health Organisation issues an alert on falsified ICLUSIG traded globally


0 Comments2 Minutes

10 February 2019

Forxiga and Edistride (Dapagliflozin) recommended by EMA as first oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes


0 Comments5 Minutes

7 February 2019

Cablivi (caplacizumab-yhdp) approved by FDA for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)


0 Comments4 Minutes

25 January 2019

First generic version of Sabril (vigabatrin) approved by FDA for the treatment of complex partial seizures


0 Comments3 Minutes

25 January 2019

Ultomiris (ravulizumab), approved by FDA for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)


0 Comments5 Minutes

11 January 2019

European Commission Approves Merck’s DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen for the Treatment of HIV-1 in Appropriate Patients


0 Comments2 Minutes

7 January 2019

FDA approves Elzonris (tagraxofusp-erzs), first treatment for rare blood disease


0 Comments3 Minutes

  • 1
  • …
  • 11
  • 12
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com